People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $352.5M | $2.8B | 2020 |
| Capstan Therapeutics, Inc. | — | Biotechnology | Series C | $227.0M | $882.9M | 2021 |
| Novus Therapeutics, Inc. | — | Biotechnology | Series D+ | $226.8M | $576.2M | 2019 |
| ImmPACT Bio USA Inc. | — | Biotechnology | Series D+ | $143.6M | $3.5B | 2020 |
| Adicet Bio, Inc. | — | Biotechnology | Series C | $116.8M | $3.3B | 2015 |
| FORE US Bio Inc. | — | Biotechnology | Series C | $99.5M | $243.5M | 2023 |
| Atox Bio Inc. | — | Biotechnology | Series B | $35.1M | $1.3B | 2017 |
Erez Chimovits at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Erez Chimovits on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michal Silverberg | 4 | 7 |
| Carl Gordon | 2 | 24 |
| Asish Xavier | 2 | 18 |
| Matthew Foy | 2 | 2 |
| Jonathan Silverstein | 1 | 10 |
| Campbell Murray | 1 | 9 |
| Judith Li | 1 | 8 |
| Simeon George | 1 | 8 |
| Timothy J. Barberich | 1 | 7 |
| John McBride | 1 | 7 |
| Chen Yu | 1 | 7 |
| James Robinson | 1 | 6 |
| Laura Shawver | 1 | 6 |
| Terry Gould | 1 | 6 |
| Bryan Smith | 1 | 6 |
| Lorence Kim | 1 | 5 |
| Casper Breum | 1 | 5 |
| Sheila Gujrathi | 1 | 5 |
| Florent Gros | 1 | 4 |
| Donald Santel | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.